Merck News (NYSE:MRK)

10/21/20169:57PMBWFDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Pati...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVA™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates making ZINPLAVA available in first quarter 2017. ZINPLAVA is indicated to reduce recurrence of Clostridium difficile... More...>>
10/21/20166:45AMBWMerck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoi...
KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy... More...>>
10/19/20167:00AMBWMerck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus ...
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of... More...>>
10/17/20165:00PMBWMerck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Micro...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Merck Research Laboratories (MRL) facilities in Rahway, N.J., and West Point, Pa., have been designated as “Milestones in Microbiology” sites by the American Society for Microbiology (ASM) for their contributions to anti-infectives... More...>>
10/14/20168:30AMBWMerck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients & the Healthc...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified (, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar... More...>>
10/10/20162:49AMPRNCAMerck Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award
Merck Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award Canada NewsWire DARMSTADT, Germany, Oct. 10, 2016 Not intended for UK- or UK-based media Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors Winners selected by internationally... More...>>
10/09/20162:44AMDJNStudy May Boost Use of Merck Lung-Cancer Drug
By Peter Loftus Patients with advanced lung cancer who took Merck & Co.'s immune-boosting drug Keytruda as their first treatment lived longer on average than those who received chemotherapy in a new study that could herald a big shift in treatment of the deadliest cancer. The finding could lead to wider use of... More...>>
10/09/20162:16AMBWTwo Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® ...
KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA... More...>>
10/09/20162:15AMBWKEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patien...
Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) Merck (NYSE:MRK), known as MSD outside the... More...>>
10/08/20168:45AMBWMerck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melan...
Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years in Patients with Ipilimumab-Refractory Advanced Melanoma Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study... More...>>
10/08/20162:15AMBWNew KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplati...
Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive... More...>>
10/07/20164:05PMBWMerck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
First Vaccine to Offer Protection Against Both Strains of Canine Influenza Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced that the U.S. Department of Agriculture has approved a license for Nobivac® Canine Flu Bivalent vaccine – the first vaccine to aid in the... More...>>
10/04/20166:03PMDJNFDA Warns on Hepatitis C Drugs
By Thomas M. Burton The Food and Drug Administration is warning about the risk of reactivation of hepatitis B among patients who have had that disease and who are taking some prominent and expensive newer medicines for hepatitis C. The federal agency said it is requiring a so-called black-box warning in the labels for... More...>>
10/04/20164:10PMGLOBENewLink Genetics Awarded $25 Million Contract from BARDA for Investigational Ebola Zaire Vaccine (V920)
AMES, Iowa, Oct. 04, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has issued a $24.8 million contract to a subsidiary of NewLink Genetics to... More...>>
10/03/201611:00PMDJNSamsung Affiliate Seeks European Approval for Herceptin Copy
SEOUL—Samsung Group's biologic drug development affiliate said Tuesday that it submitted a near-replica of blockbuster breast cancer drug Herceptin for regulatory approval in Europe, underscoring the South Korean conglomerate's growing ambitions in the field of biosimilars. Samsung Bioepis Co. develops... More...>>
10/03/20168:00AMBWMerck to Present New Data on ZEPATIER™ (elbasvir & grazoprevir) & Chronic Hepatitis C Clinical Development Programs at The ...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting® 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will... More...>>
10/02/201611:40PMDJNNovo Nordisk Bets on Riskier Insulin Research
Nearly 10 years ago, executives at Novo Nordisk A/S wondered whether the company's decadeslong quest to make ever-better insulin had finally come to an end. The trigger was an impressive set of results for the company's newest insulin that suggested the product would be difficult to improve upon. "We just... More...>>
09/29/20161:06PMBWMerck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness
Merck (NYSE:MRK), known as MSD outside the United States and Canada, commends the government of Guatemala on being the fourth country in Latin America to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis). This announcement comes one year after the international... More...>>
09/29/20169:00AMBWMerck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States
$2 Million Grant Boosts Efforts to Prevent Type 2 Diabetes in Participants with Prediabetes The Merck Foundation and YMCA of the USA (Y-USA) announced today that the Merck Foundation has provided a grant of $2 million over three years to support efforts to expand the YMCA’s Diabetes Prevention Program (YMCA’s DPP... More...>>
09/28/20168:21AMBWMSD Animal Health engagiert sich bei der weltweiten Bekämpfung von Tollwut mit bislang mehr als zwei Millionen gespendeten I...
MSD Animal Health (in den USA und Kanada unter dem Namen Merck Animal Health bekannt) kann mit bislang mehr als zwei Millionen gespendeten Dosen des Tollwutimpfstoffs NOBIVAC® an Organisationen, die sich für die Ausrottung dieser vollständig vermeidbaren Krankheit einsetzen, im Kampf gegen die Tollwut hervorragende... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20161023 03:21:36